Cannapharmarx (CPMD) AI Stock Analysis

61 Followers

Cannapharmarx

(Other OTC:CPMD)

Select Model

Rating:42Neutral

Price Target:$0.01▲(400.00% Upside)

Action:upgraded

Date:08/19/26

The overall score is driven primarily by very weak financial performance, with rapid revenue growth outweighed by large ongoing losses, deeply negative equity, and a highly leveraged balance sheet; technical signals are limited and essentially neutral, while valuation remains unattractive due to unprofitability and lack of income data, together placing the stock in a high-risk, low-scoring range.

Positive Factors

Revenue GrowthRapid revenue growth indicates improving commercial traction and customer adoption. Although growth comes from a small base, continued expansion could strengthen the operating platform if the company converts sales into healthier gross margins.

Negative Factors

Persistent Negative EquityA persistent equity deficit indicates accumulated losses have overwhelmed the capital structure. This weakens financial flexibility, limits access to conventional financing and increases the likelihood of dilution or restructuring over the medium term.

Cannapharmarx (CPMD) vs. SPDR S&P 500 ETF (SPY)

Not enough price history over this period.

Market Cap: $1.06M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.1
Beta (1Y): -0.16
Revenue Growth: 24.81%
EPS Growth: -98.84%
Country: US
Employees: 26
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Cannapharmarx Business Overview & Revenue Model

Company Description

CannaPharmaRX, Inc. is a Canadian enterprise actively involved in the cannabis sector. The company focuses on identifying, acquiring, and developing diverse projects for cultivating cannabis. Founded in 1998, its main offices are located in Calgary,...

How the Company Makes Money

null

Cannapharmarx Financial Statement Overview

Summary

Rapid early-stage revenue growth is overshadowed by persistently large operating and net losses, deeply negative and worsening shareholders’ equity, high leverage, and only recently positive but still modest operating and free cash flow, leaving the company in a high-risk financial position.

Income Statement

22Negative

Balance Sheet

12Very Negative

Cash Flow

28Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.70M	1.36M	820.14K	0	0	0
Gross Profit	-1.51M	-2.08M	-2.94M	-65.56K	-295.00K	-14.36K
EBITDA	-7.78M	-3.25M	-7.53M	-1.45M	-4.91M	-2.61M
Net Income	-11.32M	-11.13M	-9.91M	3.69M	-8.53M	-8.83M
Balance Sheet
Total Assets	6.89M	7.02M	10.84M	11.75M	5.41M	114.33K
Cash, Cash Equivalents and Short-Term Investments	555	1,804	2,156	650	2,317	27.77K
Total Debt	20.63M	20.65M	14.06M	12.94M	14.52M	9.02M
Total Liabilities	37.72M	37.17M	30.65M	23.90M	22.76M	13.04M
Stockholders Equity	-30.83M	-30.15M	-19.81M	-12.15M	-17.34M	-12.93M
Cash Flow
Free Cash Flow	253.22K	-794.62K	-1.70M	-2.36M	-1.56M	-2.42M
Operating Cash Flow	258.74K	-789.10K	-1.70M	-2.27M	-1.45M	-2.41M
Investing Cash Flow	-60.64K	-5,519	0	-80.63K	-116.00K	493.62K
Financing Cash Flow	156.50K	794.27K	1.70M	2.35M	1.40M	1.30M

Cannapharmarx Risk Analysis

Cannapharmarx disclosed 63 risk factors in its most recent earnings report. Cannapharmarx reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.While a major part of our business strategy is to pursue strategic acquisitions, we may not be able to identify businesses for which we can obtain necessary financing to acquire on acceptable terms, face risks due to additional indebtedness, and our acquisition strategy may incur significant costs or expose us to substantial risks inherent in the acquired business's operations.Q4, 2022

2.We may not be able to protect intellectual property that we hope to acquire, which could adversely affect our business.Q4, 2022

Cannapharmarx Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CPMD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INM	45Neutral	$8.95M	-0.51	794.93%	―	-82.91%	55.05%
XWEL	43Neutral	$7.13M	-0.13	317.52%	―	-7.58%	-30.33%
YCBD	43Neutral	$4.45M	-1.37	-34.25%	―	10.01%	95.01%
CPMD	42Neutral	$1.42M	-0.09	39.79%	―	24.81%	-98.84%
IMCC	28Underperform	$1.23M	-0.03	841.81%	―	-11.91%	-285.26%

* Healthcare Sector Average

Performance Comparison

CPMD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CPMD	Cannapharmarx	―	―	―
XWEL	Xwell, Inc.	0.66	-0.23	-25.62%
INM	Inmed Pharmaceuticals Inc.	1.68	-0.05	-2.89%
YCBD	Cbdmd INc	0.42	-0.40	-48.90%
LEXX	Lexaria Bioscience Corp.	4.03	-12.17	-75.12%
IMCC	Im Cannabis Corp	0.72	-39.18	-98.19%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 19, 2026

Cannapharmarx AI Stock Analysis